Crossmark

Mesenchymal Stem Cell-based Apelin Gene Therapy Improves Pulmonary Artery Remodeling in Monocrotaline-induced Pulmonary Hypertension Through PI3K/AKT/eNOS and ERK1/2 Signaling Pathways

Crossref DOI link: https://doi.org/10.1007/s12265-025-10612-3

Published Online: 2025-04-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Li

Wang, Weijian

Wu, Ting

Chen, Liang

Zong, Gangjun https://orcid.org/0000-0002-9119-0705
Funding

Funding for this research was provided by:

Medical Scientific Research Project of Wuxi Health Commission (Q202041)

Jiangsu Commission of Health (ZD2021020)
License Information

Text and Data Mining valid from 2025-04-01

Version of Record valid from 2025-04-01
More Information

Article History

Received: 27 February 2024

Accepted: 25 March 2025

First Online: 1 April 2025

Declarations

:

: All animals care and experimental procedures was approved by the Ethical Review Board of the 904th Hospital of People's Liberation Army of China (Ethical approval project: research of the efficacy and mechanism of mesenchymal stem cell-based apelin gene therapy for the treatment of pulmonary hypertension; Approval date: October 20, 2020; Approval number: E202041). The study protocol conformed to the ISSCR guidelines and ARRIVE guidelines.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below